Compare Hims and Hers Health Inc (HIMS) vs Norfolk Southern Corporation (NSC) Price & Performance

Hims & Hers Health trades at $32.70, down 0.43% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company reported 2025 revenue of $2.35 billion and net income of $128.37 million, though 2026 projections indicate a net loss. Recent news highlights executive departures and anticipation for Q2 2026 earnings on August 10, 2026.

The investment outlook is cautiously optimistic, supported by a 35% analyst buy rating and a $33.57 consensus price target. Key opportunities include growth in the weight-loss drug segment and international expansion. Risks involve profitability volatility, intense competition, and reliance on telehealth regulatory frameworks. The stock's valuation remains elevated with a P/E of 57.14, demanding strong future earnings growth to justify current levels.

Norfolk Southern (NSC) trades at $334.97, down 1.53% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 21.91% net income margin and has beaten earnings estimates for three consecutive quarters. Key developments include the pending Q2 2026 earnings report on July 23, 2026, and ongoing regulatory review of the proposed merger with Union Pacific, which dominates recent news coverage.

The investment outlook is cautiously optimistic, supported by earnings momentum and a consensus price target of $344.40 offering modest upside. Risks include potential regulatory hurdles for the merger, declining revenue projections for 2026, and elevated valuation multiples. The stock's current price near resistance levels suggests near-term volatility around earnings could present entry opportunities for long-term investors.